SeeThruEquity Initiates Research Coverage on OxySure Systems with Target Price of $1.27

New York, NY / May 7, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on OxySure Systems, Inc. (OTCQB: OXYS).

"OxySure’s flagship product to create oxygen for emergency situations has the potential to be as ubiquitous as other safety equipment like fire extinguishers and defibrillators, which we find intriguing," remarked Ajay Tandon, CEO of SeeThruEquity. "The technology of combining inert powders to create oxygen for medical use is patented and is approved by the FDA for sale over the counter.  We are impressed with OXYS’s addressable market and product potential and are initiating coverage with a price target of $1.27 per share."

Additional investment highlights are as follows:

The OxySure Model 615 offers several competitive advantages versus other respiratory products currently in use. It poses little-to-no risk of explosion, fire, environmental damage or toxicity, requires no prior training, has low maintenance needs, costs less and does not require a prescription. The company can sustain these advantages via its patents and registered trademarks, both in the U.S. and abroad. We believe the Model 615 is a compelling product that can gain wider market acceptance beyond OxySure’s current customer base.

    - Relative to the OxySure’s current core K-12 education market, the growth opportunities are tremendous and include such other verticals as colleges, churches / places of worship, manufacturing / commercial facilities, municipalities, aviation, mining, military, wound care, skin care, automotive, and sports and recreation. International expansion is another avenue for growth, with management focusing on expanding its existing footprint in 12 countries while holding ongoing discussions to enter other geographies.

    In addition to entering new markets, there are two catalysts that have the potential to increase demand for OxySure’s products. First, the company plans to pursue to legislative and regulatory efforts that could mandate the placement of one or more on-demand oxygen supply sources at school campuses, manufacturing facilities, recreational vehicles and other properties. Second, management is planning to have buyers of its products qualify for insurance benefits, including reimbursement by insurance plans and underwriting discounts. Although still in the early stages, any positive development on these fronts could accelerate OxySure’s already strong top-line growth.

      The report is available here: OxySure Systems Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.

      Please review important disclosures on our website at

      About SeeThruEquity

      SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

      For more information visit

      About OxySure Systems

      OxySure Systems, Inc. is a Frisco, Texas-based medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments.


      Ajay Tandon


      (646) 495-0939

      SOURCE: SeeThruEquity

      Release ID: 43478